NCT04959201View on ClinicalTrials.gov

Combination of NMDA-enhancing and Antioxidant Treatments for Schizophrenia

PHASE2RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

November 30, 2020

Primary Completion Date

December 31, 2026

Study Completion Date

March 31, 2027

Conditions
Schizophrenia
Interventions
DRUG

NMDAE plus AO

Use of an NMDA enhancer plus a drug with antioxidant property for the treatment of schizophrenia.

DRUG

NMDAE plus Placebo Cap

Use of an NMDA enhancer plus placebo as a comparator.

Trial Locations (1)

Unknown

RECRUITING

Department of Psychiatry, China Medical University Hospital, Taichung

All Listed Sponsors
collaborator

Ministry of Science and Technology, Taiwan

OTHER_GOV

lead

China Medical University Hospital

OTHER